EFFECT-BACK: EFFects of EXPosure and Cognitive-behavioural Therapy for Chronic BACK Pain

Sponsor
University of Koblenz-Landau (Other)
Overall Status
Recruiting
CT.gov ID
NCT05294081
Collaborator
(none)
380
5
2
26
76
2.9

Study Details

Study Description

Brief Summary

The overall aim of the present study is to compare two different psychological methods, Cognitive Behavioural Therapy (CBT) and Graduated Exposure in vivo (EXP) in the treatment of chronic back pain with regard to effectiveness and improvement of pain related disability.

Exploratory research will also be conducted to identify predictors of which patient groups benefit more from which method. This should optimise treatment options and create effective treatment offers for subgroups of pain patients.

Exposure therapy is an effective and economical treatment modality and was shown in a previous pilot study to be superior to CBT in reducing perceived movement limitation. CBT, on the other hand, appeared to be more effective in establishing coping strategies. With the help of the current study it should be possible to compare the effectiveness of both treatment methods and, in perspective, to identify those patient groups that benefit from exposure therapy and thus create a tailor-made treatment programme for subgroups of pain patients.

A total of 380 patients (age: ≥ 18) with chronic back pain and a sufficient degree of impairment will be included and analysed in the study.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Exposure therapy
  • Behavioral: Cognitive behavioral therapy
N/A

Detailed Description

According to a recently published study by the Robert Koch Institute with over 62 000 participants, one in six men (17.1%) and one in four women (24.4%) in Germany reported having suffered from chronic low back pain (CLBP) in the last 12 months. CLBP is a major cause of medical costs, absenteeism and disability. Despite apparent advances in medical care, the prevalence of CLBP continues to rise.

According to current guidelines, most of the commonly offered treatments such as injections or surgery are ineffective; only pharmacotherapy shows small effects but carries a high risk of side effects.

Cognitive behavioural therapy (CBT), multidisciplinary approaches with psychological treatment components such as CBT and exercise, supported by psychological elements, improve pain and condition-related disability in the long term. Disappointingly, however, in most studies the effects of multidisciplinary or psychological treatment approaches are small to moderate, and in the case of multidisciplinary approaches, do not always justify the high costs of inpatient programmes. In outpatient care, specific psychological services in addition to pharmacotherapy and physiotherapy are rare.

EXP treatment for pain is a rarely used psychological treatment that specifically addresses the avoidance of physical activity in people with CLBP. In a previous pilot study with 88 participants, the investigators conducted for the first time a short (10 sessions) and a longer (15 sessions) outpatient EXP therapy programme and compared it with a standard 15-session CBT programme:

  • EXP was more effective than CBT in reducing movement-related impairment.

  • EXP-short outperformed EXP-long in efficiency after 10 sessions, meaning that individuals improved faster when offered fewer sessions.

  • EXP could be safely delivered in the outpatient psychological setting, however CBT was more effective than EXP in improving coping strategies.

A specific behavioural measure, the "BAT-BACK" test, successfully identified participants who benefited from EXP in terms of a reduction in pain-related impairment. Therefore, in the future, EXP therapy could be a tailored treatment option to achieve better treatment outcomes in subgroups of CLBP patients. However, studies with more participants are needed to further clarify whether EXP is successful and for which subgroup of patients. The proposed study would be the first to aim to find out which patient group is more likely to benefit from EXP and which from CBT.

Research question and rationale for the project:

Society is currently faced with the challenge of a widespread disease without being able to offer satisfactory treatment options. A comparison of an already established treatment method (CBT) with a still less known and used treatment method (EXP) should create starting points here. In addition, tailoring chronic pain treatment specifically to subgroups of pain patients could improve care.

In addition, EXP therapy is a promising and cost-effective treatment option that could easily be incorporated into multidisciplinary programmes for inpatients or offered by outpatient psychotherapists as part of the newly established 12-hour brief psychotherapy. In order to validate the preliminary results of the pilot study and to answer open questions, a multicentre study with a larger number of participants is implemented.

The study should also lead to a larger number of therapists trained in EXP therapy in different regions in Germany and to an increase in the visibility of the treatment manuals and could lead to a more frequent use of EXP for the benefit of the CLBP population. By publishing the results, the investigators hope to raise awareness, especially among psychological psychotherapists, that brief, manualised, focused treatments may be sufficient to reduce the burden of chronic pain. The identification of predictors will help all practitioners involved in the treatment of chronic pain to identify those patients who are more likely to benefit from EXP and those who are more likely to benefit from CBT.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
380 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This is a prospective, multicentre, randomised, controlled, open-label, two-arm intervention study with a parallel group design. Two parallel groups are formed, the intervention group receives 10 sessions of EXP therapy, the control group receives 10 sessions of CBT. The assignment to the therapy methods is randomised. This is a multicentre study, the study will be conducted at 5 centres throughout Germany. A total of 380 patients will be included. Per study arm, 190 patients must be included.This is a prospective, multicentre, randomised, controlled, open-label, two-arm intervention study with a parallel group design. Two parallel groups are formed, the intervention group receives 10 sessions of EXP therapy, the control group receives 10 sessions of CBT. The assignment to the therapy methods is randomised. This is a multicentre study, the study will be conducted at 5 centres throughout Germany. A total of 380 patients will be included. Per study arm, 190 patients must be included.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
EFFECT-BACK: Tackling Back Pain - Effects of Exposure Therapy and Cognitive Behavioural Therapy for Chronic Back Pain
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Sep 30, 2024
Anticipated Study Completion Date :
Sep 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Exposure (EXP)

Exposure in vivo for fear avoidant chronic low back pain patients. This treatment means that the individual is exposed to movements and tasks that have been avoided due to fear of (re)injury. The treatment begins after three educational lessons including the rational and developing a fear hierarchy. Exposure phase includes 10 exposures sessions which are highly individualized. Behavioral experiments can be included to correct catastrophic misinterpretations. The main purpose of this intervention type is to reduce pain related disability via diminishing fear avoidance.

Behavioral: Exposure therapy
10 sessions based on an individualized pain hierarchy

Active Comparator: Cognitive Behavioural Therapy (CBT)

Cognitive behavioural psychotherapy for fear avoidant chronic low back patients. The therapy is modularized in three main parts. The educational lesson is followed by the module graded activity which represents the behavioral part of the program. The second module comprises relaxation. And the last part contains cognitive interventions. Cognitive behavioural intervention techniques are employed to support the patient in the process of coping with chronic pain: i.e. reduction of disability and improving functional ability.

Behavioral: Cognitive behavioral therapy
10 sessions with graded activity, relaxations techniques and cognitive interventions

Outcome Measures

Primary Outcome Measures

  1. Change in pain related disability [from Baseline to Posttest (an expected average of 15 weeks) to Follow Up Assessment (an expected average of 6 month after Posttest)]

    Clinically significant change in pain-related impairment at the end of therapy and at 6-month follow-up compared to baseline. Quebec Back Pain Disability Scale (QBPDS). Each item is scored from 0 to 5 (0 = not difficult at all, 5 = unable to do). Higher total scores reflect higher disability.

Secondary Outcome Measures

  1. Change in pain disability [from Baseline to Posttest (an expected average of 15 weeks) to Follow Up Assessment (an expected average of 6 month after Posttest)]

    Clinically significant change in pain-related impairment at the end of therapy and at 6-month follow-up compared to baseline. Pain Disability Index (PDI). Each item is scored from 0 to 10 (0 = no disability, 10 = maximum disability). Higher total scores reflect higher interference of pain with daily activities.

  2. Change in pain intensity [from Baseline to Posttest (an expected average of 15 weeks) to Follow Up Assessment (an expected average of 6 month after Posttest)]

    Clinically significant change in pain intensity at the end of therapy and at 6-month follow-up compared to baseline. adjusted 11-point Scale of the German Pain Questionaire (Deutscher Schmerzfragebogen, DSF). 3 Items, each item is scored from 0 to 10 (e.g. 0 = no pain, 10 = strongest pain). A higher score reflects stronger pain.

  3. Change in coping [from Baseline to Posttest (an expected average of 15 weeks) to Follow Up Assessment (an expected average of 6 month after Posttest)]

    Change in coping at the end of therapy and at 6-month follow-up compared to baseline. Coping scale from the German questionnaire for the assessment of pain processing (Fragebogen zur Erfassung der Schmerzverarbeitung, FESV-BW). Each item is scored from 1 to 6 (1 = not true at all, 6 = completely true). Higher total scores reflect more frequent use of different coping strategies.

  4. Change in emotional distress [from Baseline to Posttest (an expected average of 15 weeks) to Follow Up Assessment (an expected average of 6 month after Posttest)]

    Change in depression at the end of therapy and at 6-month follow-up compared to baseline. Depression scale of the Hospital Anxiety and Depression Scale (HADS). Each item is scored from 0 to 3. Higher total scores reflect stronger anxiety or depressiveness.

  5. Change in pain catastrophizing [from Baseline to Posttest (an expected average of 15 weeks) to Follow Up Assessment (an expected average of 6 month after Posttest)]

    Change in catastrophizing at the end of therapy and at 6-month follow-up compared to baseline. Pain Catastrophizing Scale (PCS). Each item is scored on a scale of 0 to 4 (0 = not at all, 4 = all the time). Higher total scores reflect more catastrophising thoughts.

  6. Change in kinesiophobia [from Baseline to Posttest (an expected average of 15 weeks) to Follow Up Assessment (an expected average of 6 month after Posttest)]

    Change in kinesiophobia at the end of therapy and at 6-month follow-up compared to baseline. Photo Series of Daily Activities (PHODA). Each item is scored from 0 to 100 (0 = not harmful at all, 100 = extremely harmful). Higher scores reflect higher perceived harmfulness.

  7. Change in pain anxiety [from Baseline to Posttest (an expected average of 15 weeks) to Follow Up Assessment (an expected average of 6 month after Posttest)]

    Change in pain anxiety avoidance at the end of therapy and at 6-month follow-up compared to baseline. Pain Anxiety Symptom Scale (PASS-20). Each item is scored from 0 to 5 (0 = never, 5 = always). Higher total scores reflect more fear of pain.

  8. Change in psychological inflexibility [from Baseline to Posttest (an expected average of 15 weeks) to Follow Up Assessment (an expected average of 6 month after Posttest)]

    Change in psychological inflexibility at the end of therapy and at 6-month follow-up compared to baseline. Psychological Inflexibility in Pain Scale (PIPS). Each item is scored from 1 to 7 (1 = never true, 7 = always true). Higher total scores reflect higher inflexibility because of pain.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Chronic low back pain (duration > 6 months, pain on most days of the week)

  • Sufficient level of disability, as defined by QBPDS ≥ 15 (Quebec Back Pain Disability Scale)

  • Age 18 and above

  • Agreeing to participate, verified by completion of informed consent

Exclusion Criteria:
  • Back surgeries during the last six months or planned surgeries

  • Red Flags

  • inability to read or write in German

  • pregnancy

  • severe alcohol or drug addiction

  • psychotic disorders

  • another current psychological treatment

  • physical inability to attend sessions

  • parallel participation in another intervention study

Depression will be controlled for, medication will be required to stay stable until Follow-up and any changes will be controlled for, on-demand ("rescue") medication will be not allowed.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Universität Koblenz - Landau Landau RLP Germany 76829
2 Essener Rückenschmerzzentrum, Universitätsklinikum Essen Essen Germany 45147
3 Schmerzzentrum, Ruprechts - Karls Universität Heidelberg Heidelberg Germany 69120
4 Poliklinische Institutsambulanz für Psychotherapie Mainz Germany 55122
5 Phillips-Universität Marburg Marburg Germany 35037

Sponsors and Collaborators

  • University of Koblenz-Landau

Investigators

  • Study Director: Julia A Glombiewski, Prof. Dr., University of Koblenz- Landau, Department of Clinical Psychology and Psychotherapy

Study Documents (Full-Text)

More Information

Publications

Responsible Party:
University of Koblenz-Landau
ClinicalTrials.gov Identifier:
NCT05294081
Other Study ID Numbers:
  • EFFECT-BACK1/2022
First Posted:
Mar 24, 2022
Last Update Posted:
Jul 29, 2022
Last Verified:
Jul 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Koblenz-Landau
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 29, 2022